Article
Bayer Wants Patient Engagement in Early Drug Development
Bayer is collaborating with MD Anderson in Texas to develop a questionnaire that will query a patient's disease-related symptoms, a step to include PROs in early drug development which could help reduce adverse effects in the final product.
When cancer patients take part in a clinical trial to develop new therapies, they and their physicians want to know how they will feel and function during treatment. A new collaboration between Bayer and The University of Texas MD Anderson Cancer Center will go straight to the patients to learn how certain investigational new drugs affect them. The project will involve the use of questionnaires to assess how a drug may impact a patient’s disease-related symptoms.
“Fit-for-purpose patient-reported-outcome (PRO) measures are an invaluable resource for helping us to better understand how patients are actually being affected by new therapies,” said Charles Cleeland, Ph.D., chair of symptom research at MD Anderson. “This will be especially important in the developmental pathway of new drugs, given that these PRO measures will enhance information about treatment tolerability and potential symptom-reduction benefit earlier in the drug development process.”
Link to the complete news release by The MD Anderson Cancer Center: http://bit.ly/1CvkpRs
